Who is sponsoring NCT03569566?

NCT03569566 is sponsored by University of South-Eastern Norway.

What drugs are being tested in NCT03569566?

Interventions in NCT03569566: Age, Genes, Training, Tickbourne Disease and Endurance.

What condition does NCT03569566 study?

NCT03569566 studies Exercise Physiology.

Is NCT03569566 still recruiting?

NCT03569566 is currently completed. Last updated 4 August 2022.

Last reviewed 2022-08-04 · How we verify

NCT03569566

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performance Determinants Factors in Elite Endurance Athletes.

Completed Last updated 4 August 2022

What this trial tests

trial testing Age, Genes, Training, Tickbourne Disease and Endurance in Exercise Physiology in 54 participants. Completed in 31 December 2021.

Timeline

27 June 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	University of South-Eastern Norway
Status	Completed
Study type	OBSERVATIONAL
Enrollment	54
Start date	27 June 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Norway

Drugs / interventions tested

Age, Genes, Training, Tickbourne Disease and Endurance

Conditions studied

Exercise Physiology — all drugs for Exercise Physiology →

Sponsor

University of South-Eastern Norway

Who can join

Adults 16 to 50, any sex, with Exercise Physiology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several studies have investigated determinant factors for endurance performance among different athletes, untrained individuals and patients focusing on the impact of age, genes and training intensity. A further step in this research will be to investigate the impact of age, genes, training intensity and history of tick-bourne disease on endurance performance in elite endurance athletes. We are planning a project with a two-step model. In step one we will, in a cross-sectional study design, investigate potential relationships between age, training intensity, training volume, genes, exosomes and history of tick-bourne disease and physiological variables and endurance performance. In step two we will investigate differences in training adaptation by observing and monitoring all training done by the participants during a 6-months period. The participants will be tested for several physiological variables before, after 3- months and after this period. We will also investigate the impact of age, training intensity, training volume, genes and history of tick-bourne disease on the results from the physiological tests and performance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217

Verify or expand the search:

Other recruiting trials for Exercise Physiology

Currently open trials in the same condition.

NCT07449663 — SPORT-SPECIFIC HIIT IN ELITE KICKBOXERS · NA · active not recruiting
NCT07393841 — Molecular Indicators of Systematic Fitness · recruiting

Other University of South-Eastern Norway trials

Trials by the same sponsor.

NCT06809244 — Strength Training and Eating Disorders · NA · enrolling by invitation
NCT03081520 — Affective Responses Following Aerobic Exercise With Different Intensities · NA · completed
NCT03906851 — Active and Healthy Kids in Telemark - a School Based Health Promoting Intervention · NA · completed
NCT03078673 — Cross Country Poling Specific Motor Skill- and Strength Training. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03569566 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of South-Eastern Norway
Last refreshed: 4 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03569566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing